On December 22, Shionogi revealed a definitive agreement to acquire the amyotrophic lateral sclerosis (ALS) portfolio from Tanabe Pharma. The centerpiece of this acquisition is the Radicava product line—encompassing both intravenous and oral formulations—along with its integrated commercial infrastructure.
Shionogi will execute a lump-sum payment of $2.5 billion to secure these operations, with additional future royalties contingent upon specific performance conditions. Once the transaction concludes in April, it is expected to contribute approximately $700 million in annual global revenue to Shionogi’s balance sheet.
Beyond immediate financial gains, Shionogi’s strategic objective is to leverage Radicava’s established distribution network in the U.S. This “rare disease platform” will serve as a vital conduit for the company’s upcoming pipeline, including treatments for Fragile X syndrome and Pompe disease. For the seller, Tanabe Pharma, this divestiture follows a major restructuring and rebranding effort earlier this year as part of its transition under new ownership.